Mylan Inc Subsidiary Matrix Laboratories Receives FDA Approval
Finance World News Update by EQUITIES Magazine
Beverly Hills 11/13/2009 06:52 PM GMT (TransWorldNews)
Mylan Inc’s subsidiary, Matrix Laboratories, received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application’s (ANDA) Lansoprazole delayed-release capsules in two dosage forms (15 mg and 30 mg). The parent company plans to begin shipment of the product immediately.
A generic version of Takeda Pharmaceuticals’ proton pump inhibitor Prevacid DR Capsules, this most recent approval comes after their tentative FDA approval for the company's fixed-dose combination of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate tablets for the treatment of HIV.
Right now, Mylan has 125 ANDAs pending FDA approval representing annual brand sales of $84.1 billion.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
info@equitiesmagazine.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
EQUITIES Magazine
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
